Global dosing hold in fitusiran trials initiated by Sanofi Genzyme to investigate new adverse events

A joint statement of the World Federation of Hemophilia (WFH), European Haemophilia Consortium (EHC) and National Hemophilia Foundation (NHF)

November 6, 2020 – The WFH, EHC and NHF have learned of and subsequently confirmed a decision by Sanofi Genzyme to initiate a voluntary sponsor-led global dosing hold on its full clinical development program for fitusiran due to the identification of new adverse events.

CLICK HERE TO ACCESS FULL STATEMENT